Australia's most trusted
source of pharma news
Friday, 18 October 2024
Posted 24 July 2024 AM
A new report has exposed how much money was likely left on the table when pharmas couldn't keep up with demand for GLP-1 RA drugs after they were revealed to be effective against obesity.
A drug utilisation sub committee (DUSC) outcome statement has revealed the extent of the hit that GLP-1 treatments took at the end of 2022 when shortages were at their peak .
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.